• Hip-Bearing System
• Knotless Implant System
• New Dosage Strength of FOSAMAX PLUS D
  
  

Hip-Bearing System

DePuy Orthopaedics, Inc., has announced a new option for restoring hip mobility in patients who require total hip replacement: the Pinnacle® Acetabluar Cup System Ultamet® XL hip bearing. This modular system provides advanced technology for recreating the natural ball-and-socket joint of the hip to help increase joint stability, range of motion, and longevity of the implant.1,2 The Ultamet XL metal-on-metal bearing is used with DePuy’s exclusive Pinnacle Acetabular Cup System, providing surgeons with the option of choosing a polyethylene or metal insert for use with the same outer titanium cup that replaces the socket of the natural hip. DePuy Orthopaedics lists the following as key benefits: Greater range of motion and stability. Ultamet XL bearings offer up to 159° range of motion and 20 mm of jump distance (compared with 28- and 36-mm Ultamet bearings). Proven technology. The latest data presented at the 2007 AAOS annual meeting show that the Pinnacle Acetabular Cup System has demonstrated 99.9% survivorship at 5 years.3 Significant wear reduction. In a recent wear-simulator study, 44-mm Ultamet XL bearings reduced early wear (run-in wear) by 92% compared with traditional metal-on-metal bearings.4 Optimized bone preservation. By maximizing the size of the femoral head in relation to the outer diameter of the acetabular shell, Ultamet® XL bearings allow for enhanced stability while preserving acetabular bone. For more information, contact DePuy Orthopedics 700 Orthopaedic Drive Warsaw, Indiana 46581 Phone (800) 366-8143 www.depuyorthopedics.com References Data on file at DePuy Orthopaedics, Inc. Engh A., et al. A randomized prospective evaluation of outcomes after total hip arthroplasty using cross-linked Marathon and non—cross-linked Enduron polyethylene liners. J Arthroplasty. 2006; 21(6; suppl. 2). Kindsfater K, Barrett W, Dowd J, Southworth C, Cassell M. Poster #P077. Midterm survival of the Pinnacle Multi- Liner Acetabular Cup in a prospective multi-center study. 2007 AAOS Annual Meeting. Data on file at DePuy Orthopaedics, Inc.

Knotless Implant System

ArthroCare® Corp. announced today it has received 510(k) clearance from the U.S. Food and Drug Administration to market its Magnum PI Knotless Implant System, which utilizes implants made of polyetheretherketone (PEEK) for the attachment of soft tissue to bone. The Magnum PI Knotless Implant System provides surgeons who prefer non-metallic anchors with a radiolucent elastic plastic (PEEK) anchor product line that utilizes the Opus® platform’s proven technology and operating principles. The Magnum PI Knotless Implant System can be used in shoulderrelated procedures such as rotator cuff repairs and in Achilles tendon repair in the foot, among several other indications. ArthroCare’s knotless implant systems are designed to enable trained physicians to perform such surgeries faster and more easily. For additional information, contact ArthroCare Corporation 7500 Rialto Boulevard, Building Two, Suite 100, Austin, Texas 78735 Phone (512) 391- 3900 www.arthrocare.com

New Dosage Strength of FOSAMAX PLUS D

Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new dosage of FOSAMAX PLUS D™(alendronate sodium/cholecalciferol), a single, once-weekly tablet containing FOSAMAX® (alendronate sodium) 70 mg and 5,600 international units (IU) of vitamin D3 (cholecalciferol). The National Osteoporosis Foundation (NOF) recently updated its recommendations for calcium and vitamin D intake, advocat ing 800 to 1,000 IU of vitamin D3 per day for adults over 50. Merck notes that, consistent with these recommendations, FOSAMAX PLUS D (70 mg alendronate/5,600 IU vitamin D3) is now the appropriate dose for most postmenopausal women with osteoporosis being treated with FOSAMAX PLUS D. Patients at increased risk for vitamin D deficiency (eg, those who are nursing-home bound, chronically ill, over the age of 70 years) or with gastrointestinal malabsorption syndromes may require vitamin D supplementation in addition to that provided in FOSAMAX PLUS D. FOSAMAX PLUS D is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of osteoporosis, FOSAMAX PLUS D increases bone mass and reduces the incidence of fractures, including those of the hip and spine. FOSAMAX PLUS D is also indicated to increase bone mass in men with osteoporosis. In a press release in early May, contact Contact Merck & Co., Inc. One Merck Drive, P.O. Box 100, Whitehouse Station, New Jersey 08889 Phone (908) 423-1000 www.merck.com